论文部分内容阅读
为探讨乳腺癌ER、PR、c -erbB - 2测定的临床意义 ,应用乳腺癌受体酶联雌二醇与孕酮亲和组化检测法 ,检测 137例乳癌激素受体状况 ,同时应用ABC免疫组化法进行c -erbB - 2表达测定。结果发现 137例乳腺癌ER( +)PR( +) 66例 ,ER( - )PR( - ) 42例 ,ER( +)PR( - ) 16例 ,ER( - )PR( +) 13例。ER、PR阳性乳腺癌的c -erbB - 2阳性率分别为 2 2 0 %和 2 0 3% ,ER、PR阴性者分别为 70 9%和 70 7% ,随诊 2年以上 ,激素受体阳性复发率约为 4 % ,阴性者约为 13% ,c -erbB - 2阳性复发率为 14 0 % ,阴性者为 2 5% (P <0 0 5)。结果强调ER、PR水平与c -erbB - 2表达有关 ,激素受体阳性 ,c-erbB - 2阴性者预后及对内分泌治疗反应较同期病人相对好。
To investigate the clinical significance of ER, PR and c-erbB-2 in breast cancer, the status of 137 breast cancer hormone receptors was detected by using the combination of breast cancer receptor enzyme-linked estradiol and progesterone affinity assay. ABC The expression of c-erbB-2 was detected by immunohistochemistry. Results There were 66 cases of ER (+) PR (+), 42 cases of ER (-) PR (-), 13 cases of ER (+) PR (-) and 137 cases of ER (+) PR (+) in 137 cases of breast cancer. The positive rates of c-erbB-2 in ER and PR positive breast cancer were 220% and 203% respectively, while those in ER and PR negative were 70.9% and 70.7% respectively. After 2 years of follow-up, hormone receptor The positive relapse rate was about 4%, negative about 13%, c-erbB-2 positive relapse rate was 14 0%, negative 25% (P <0 05). The results emphasize that the level of ER and PR is related to the expression of c-erbB-2, the prognosis of hormone receptor positive and c-erbB-2 negative and the response to endocrine therapy are better than those of the same period.